<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 8.5: Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Diabetes/Metabolic Health */
        .module-header {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #0369a1;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #0369a1;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0f9ff;
            border: 2px solid #0ea5e9;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #0ea5e9;
        }

        .term-item .term {
            font-weight: 700;
            color: #0369a1;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #0369a1;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #bae6fd;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #0369a1;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.info {
            background: #e3f2fd;
            border-left-color: #2196f3;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #0ea5e9, #0369a1);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
            z-index: 1;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f8fafc;
            padding: 15px;
            border-bottom: 2px solid #e2e8f0;
            color: #0369a1;
            font-weight: 700;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            color: #475569;
        }

        /* Principle Cards */
        .principle-card {
            background: linear-gradient(to right, #fafafa, #ffffff);
            border-left: 5px solid #0369a1;
            padding: 24px 28px;
            margin-bottom: 18px;
            border-radius: 0 14px 14px 0;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.04);
        }

        .principle-title {
            font-weight: 700;
            color: #0369a1;
            margin-bottom: 8px;
        }

        /* Check Understanding */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #0369a1;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0f9ff;
            border-radius: 8px;
            color: #0369a1;
        }

        .answer-text.show {
            display: block;
        }

        /* References & Footer */
        .references-box {
            background: #f8fafc;
            padding: 30px;
            border-radius: 14px;
            margin-top: 50px;
            border: 1px solid #e2e8f0;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #334155;
            font-size: 16px;
        }

        .references-list {
            font-size: 13px;
            color: #64748b;
            padding-left: 20px;
        }

        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            border-radius: 12px;
            margin: 40px 0;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 8: Advanced Pathophysiology & Complications</p>
            <h1 class="lesson-title">Lesson 8.5: Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 5 of 8</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Hepatic-Metabolic Axis</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Pathophysiology: De Novo Lipogenesis</a></li>
                <li><a href="#section3"><span class="section-num">3</span>The Progression: NAFLD vs. NASH</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Diagnostic Biomarkers & Imaging</a></li>
                <li><a href="#section5"><span class="section-num">5</span>The STABLE Methodâ„¢ Intervention</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Reversibility and Coaching Strategy</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the spectrum of liver disease from simple steatosis to NASH-related cirrhosis.</li>
                <li>Explain the biochemical mechanism of de novo lipogenesis (DNL) and its link to dietary fructose and hyperinsulinemia.</li>
                <li>Identify key diagnostic markers including AST/ALT ratios and the FIB-4 index.</li>
                <li>Analyze the "Two-Hit Hypothesis" of hepatic cellular damage.</li>
                <li>Apply the STABLE Methodâ„¢ to design a liver-protective coaching protocol.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Silent Epidemic of the Metabolic Era</h3>
            <p>Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as the most common chronic liver condition worldwide, mirroring the global rise in obesity and Type 2 Diabetes. Often called the "hepatic manifestation of metabolic syndrome," NAFLD is not just a liver problemâ€”it is a central driver of systemic insulin resistance. As a coach, understanding that <span class="highlight">the liver is the metabolic clearinghouse</span> of the body is essential for managing blood sugar stability.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Steatosis</p>
                    <p class="definition">The abnormal retention of lipids (fat) within a cell, specifically hepatocytes in the liver.</p>
                </div>
                <div class="term-item">
                    <p class="term">NASH</p>
                    <p class="definition">Non-Alcoholic Steatohepatitis: A more aggressive form of NAFLD characterized by liver inflammation and cell damage.</p>
                </div>
                <div class="term-item">
                    <p class="term">De Novo Lipogenesis (DNL)</p>
                    <p class="definition">The metabolic process of converting excess carbohydrates (especially fructose) into fatty acids within the liver.</p>
                </div>
                <div class="term-item">
                    <p class="term">Hepatocytes</p>
                    <p class="definition">The primary functional cells of the liver, responsible for metabolism, detoxification, and protein synthesis.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Hepatic-Metabolic Axis</h2>
        <p>The liver plays a dual role in glucose homeostasis: it acts as both a storage site (glycogen) and a producer (gluconeogenesis). In a healthy state, insulin signals the liver to stop producing glucose and start storing it. However, in the context of Type 2 Diabetes, the liver becomes "selectively insulin resistant."</p>
        
        <p>A 2021 global meta-analysis published in <span class="highlight">The Lancet (n=1,030,160)</span> reported that NAFLD prevalence in patients with Type 2 Diabetes is approximately <span class="highlight">55.5%</span>. This suggests that over half of your diabetic clients are likely dealing with some degree of hepatic fat accumulation, whether diagnosed or not.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">70%</div>
                    <div class="stat-label">T2D Patients with NAFLD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">25%</div>
                    <div class="stat-label">Global Adult Prevalence</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">2-3x</div>
                    <div class="stat-label">Increased CVD Risk</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10%</div>
                    <div class="stat-label">Progress to NASH</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Pathophysiology: De Novo Lipogenesis (DNL)</h2>
        <p>How does sugar turn into liver fat? The answer lies in <span class="highlight">De Novo Lipogenesis (DNL)</span>. While the liver can handle moderate amounts of glucose, fructose is handled almost exclusively by hepatic tissue. Unlike glucose, fructose does not require insulin for entry into cells, but it rapidly depletes hepatic ATP and fuels the creation of palmitate (a saturated fatty acid).</p>

        <div class="alert-box info">
            <p class="alert-label">The Fructose Trap</p>
            <p>Fructose bypasses the rate-limiting enzyme phosphofructokinase. This means the liver cannot "turn off" the processing of fructose, leading to an unregulated flood of substrate that is inevitably converted into fat when energy stores are full.</p>
        </div>

        <p>In the STABLE Methodâ„¢, we focus on <strong>Evolutionary-Based Nutrition (E)</strong> to mitigate this. By reducing the "fructose load," we directly lower the substrate available for DNL, effectively "starving" the liver of the raw materials it uses to create ectopic fat.</p>

        <h2 id="section3">The Progression: NAFLD vs. NASH</h2>
        <p>It is critical to distinguish between "simple fatty liver" and "steatohepatitis." While simple steatosis is relatively benign, NASH represents a state of active cellular suicide (apoptosis) and fibrosis.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>NAFLD (Simple Steatosis)</th>
                        <th>NASH (Steatohepatitis)</th>
                        <th>Cirrhosis</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Fat Content</strong></td>
                        <td>>5% of liver weight</td>
                        <td>>5% + Inflammation</td>
                        <td>Variable (Fat may decrease)</td>
                    </tr>
                    <tr>
                        <td><strong>Cell Damage</strong></td>
                        <td>Minimal/None</td>
                        <td>Hepatocyte "Ballooning"</td>
                        <td>Extensive scarring</td>
                    </tr>
                    <tr>
                        <td><strong>Reversibility</strong></td>
                        <td>Highly Reversible</td>
                        <td>Partially Reversible</td>
                        <td>Generally Irreversible</td>
                    </tr>
                    <tr>
                        <td><strong>ALT/AST Levels</strong></td>
                        <td>Often Normal</td>
                        <td>Usually Elevated</td>
                        <td>Can be Normal or High</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Normal" Labs Trap</p>
                    <p style="color: white; margin: 0; font-size: 13px;">Client: Robert, Age 52, Type 2 Diabetic</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-info">
                        <h4>Initial Presentation</h4>
                        <p>A1c: 7.2%, ALT: 38 U/L (within "normal" range), Triglycerides: 210 mg/dL. Robert complained of persistent fatigue and "brain fog."</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Utilizing <strong>Tactical Tracking (T)</strong>, we noted Robert's glucose remained elevated (140-160 mg/dL) overnight. We implemented <strong>Active Sensitization (A)</strong> via 30 minutes of Zone 2 walking post-dinner and removed high-fructose corn syrup sources.</p>
                <p><strong>Outcome:</strong> After 12 weeks, Robert's triglycerides dropped to 115 mg/dL. His ALT dropped to 19 U/L. Despite his ALT being "normal" initially, the significant drop and triglyceride reduction indicated a clearance of hepatic fat and improved insulin sensitivity.</p>
            </div>
        </div>

        <h2 id="section4">Diagnostic Biomarkers & Imaging</h2>
        <p>As a coach, you cannot order biopsies, but you must understand how to interpret the data your client brings from their physician. The gold standard is a liver biopsy, but non-invasive tools are now the primary mode of assessment.</p>
        
        <div class="principle-card">
            <p class="principle-title">1. The AST/ALT Ratio</p>
            <p class="principle-text">In NAFLD, ALT is typically higher than AST (Ratio < 1). If AST becomes higher than ALT (Ratio > 1), it may signal the progression toward fibrosis or cirrhosis.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">2. The FIB-4 Index</p>
            <p class="principle-text">A validated score using Age, AST, ALT, and Platelet count. A score < 1.30 has a high negative predictive value for advanced fibrosis.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">3. FibroScan (VCTE)</p>
            <p class="principle-text">An ultrasound-based technology that measures "liver stiffness." Higher kilopascals (kPa) correlate with higher stages of fibrosis.</p>
        </div>

        <h2 id="section5">The STABLE Methodâ„¢ Intervention</h2>
        <p>Managing NAFLD requires a multi-pronged approach that addresses the root of metabolic dysfunction. We apply the STABLE Methodâ„¢ as follows:</p>

        <ul>
            <li><strong>Stabilization (S):</strong> Flattening the postprandial glucose curve reduces the insulin stimulus for DNL. We aim for a Time in Range (TIR) > 80%.</li>
            <li><strong>Active Sensitization (A):</strong> Resistance training increases GLUT4 translocation in muscles, diverting glucose away from the liver and into the muscle cells for storage as glycogen.</li>
            <li><strong>Biological Synergy (B):</strong> We optimize the HPA axis. High cortisol (stress) stimulates gluconeogenesis, forcing the liver to produce glucose even when the client isn't eating, worsening the fat accumulation.</li>
            <li><strong>Evolutionary Nutrition (E):</strong> Focus on high fiber-to-carb ratios and elimination of processed seed oils, which can exacerbate hepatic inflammation via the omega-6 pathway.</li>
        </ul>

        <div class="alert-box warning">
            <p class="alert-label">Coach's Note: Weight Loss vs. Liver Fat</p>
            <p>Research shows that a weight loss of just <span class="highlight">3-5%</span> can reduce hepatic steatosis, but a <span class="highlight">7-10%</span> loss is often required to improve inflammation and fibrosis in NASH (Vilar-Gomez et al., 2015).</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of hepatic pathophysiology.</p>
            
            <div class="question-item">
                <p class="question-text">Why is fructose considered more "lipogenic" (fat-producing) than glucose in the liver?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Fructose bypasses the rate-limiting enzyme phosphofructokinase, meaning the liver cannot regulate its intake. It is processed rapidly into substrate for de novo lipogenesis (DNL) regardless of the body's energy needs.</div>
            </div>

            <div class="question-item">
                <p class="question-text">A client's labs show an ALT of 45 and an AST of 25. What does this ratio typically suggest in a metabolic context?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">An ALT higher than AST (Ratio < 1) is a classic signature of NAFLD/metabolic-related liver fat accumulation. If the ratio were reversed (AST > ALT), it might suggest more advanced damage or alcohol-related issues.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>NAFLD is the "silent partner" of Type 2 Diabetes, affecting over 50% of the diabetic population.</li>
                <li>Hyperinsulinemia and high fructose intake are the primary drivers of hepatic fat via De Novo Lipogenesis.</li>
                <li>Simple fatty liver (NAFLD) is highly reversible through the STABLE Methodâ„¢ principles, particularly glucose stabilization and fructose restriction.</li>
                <li>Watch for the "Normal Lab Trap"â€”liver enzymes can appear within the reference range even when significant steatosis is present.</li>
                <li>Liver health is the foundation of blood sugar control; a fatty liver is an insulin-resistant liver.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Younossi, Z. M., et al. (2021). "The global epidemiology of nonalcoholic fatty liver diseaseâ€”A systematic review and meta-analysis." <i>The Lancet Gastroenterology & Hepatology</i>.</li>
                <li>Tilg, H., et al. (2020). "The endocrine liver: A key player in metabolic regulation." <i>Endocrine Reviews</i>.</li>
                <li>Vilar-Gomez, E., et al. (2015). "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis." <i>Gastroenterology</i>.</li>
                <li>Lustig, R. H. (2013). "Fructose: Itâ€™s alcohol without the buzz." <i>Advances in Nutrition</i>.</li>
                <li>Stefan, N., et al. (2019). "Nonalcoholic fatty liver disease and type 2 diabetes: From pathophysiology to therapeutics." <i>Diabetes Care</i>.</li>
                <li>Cusi, K. (2020). "A systemic review of the role of the liver in the pathophysiology of Type 2 Diabetes." <i>Journal of Investigative Medicine</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Diabetes & Blood Sugar Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>